AzTrials
AzTrials

Type 1 DiabetesVISCERANCT02689570

Relation of Visceral Fat and Associated Cytokines With Early Cardiovascular Complications in Type 1 Diabetes.

An observational study of Type 1 Diabetes and Coronary Artery Calcifications, run by University Hospital, Antwerp at 1 site in Belgium.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Objective: To investigate whether visceral adipose tissue (VAT) and its adipokines contribute to early signs of cardiovascular disease, meaning coronary artery calcifications (CAC) and diastolic dysfunction in type 1 diabetes (T1DM). Read more about this study

Who is it for?
Ages 18 to 75 years
What is being tested?
observational
How many people
150 participants
Where
1 siteBelgium
Study dates
Jun 2011to Jan 2017
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult type 1 diabetic patients regularly attending the out-patient diabetes clinic of the Antwerp University Hospital

Who may be able to join

  • type 1 diabetic patients (criteria for diagnosis by the American Diabetes Association
  • diabetes duration ≥5 years
  • general good health

Who cannot join

  • having experienced a major adverse cardiovascular event (myocardial infarction,stroke)
  • having cardiovascular complaints
  • pregnancy
  • having an estimated glomerular filtration ≤ 30ml/min/1.73 m²

Trial locations and contacts

1 site in 1 country.

Christophe EM De Block, MD, PhD contact

+3238214364

christophe.deblock@uza.be

Luc F Van Gaal, MD, PhD contact

+328213278

luc.vangaal@uza.be

Belgium1 site, 1 recruiting
  • Antwerp University Hospital

    Edegem, 2650

    Christophe De Block, MD PhD, +3238214364, christophe.de.block@uza.be

    Luc Van Gaal, MD PhD

    Recruiting

Other trials in Belgium

About this study

Official title: Relation of Visceral Fat and Associated Cytokines With Early Cardiovascular Complications in Type 1 Diabetes: the VISCERA Study

Objective: To investigate whether visceral adipose tissue (VAT) and its adipokines contribute to early signs of cardiovascular disease, meaning coronary artery calcifications (CAC) and diastolic dysfunction in type 1 diabetes (T1DM).

Research Design \& Methods: A cross-sectional study of T1DM patients without a history of cardiovascular disease. CAC and VAT are measured using a CT scan. CAC is scored using the Agatston method. Echocardiography is performed to assess contractile abnormalities. Serum levels of adipocytokines (adiponectin, leptin, IL-6 and TNF-a) are measured using ELISA assays.

Read the detailed description

Objective: To investigate whether visceral adipose tissue (VAT) and its adipokines contribute to early signs of cardiovascular disease, meaning coronary artery calcifications (CAC) and diastolic dysfunction in type 1 diabetes (T1DM).

Patients \& Methods:

Adult T1DM patients, aged 18-75 years, regularly attending the out-patient diabetes clinic of the Antwerp University Hospital are recruited starting from June 2011. Patients have to have a diabetes duration of ≥5 years and be in general good health to be included. Exclusion criteria are a history of a major adverse cardiovascular event (myocardial infarction, stroke), other cardiovascular complaints, pregnancy or a glomerular filtration rate ≤30 ml/min/1.73 m².

All participants sign an informed consent form. This study is conducted in accordance with the amended Declaration of Helsinki. The research protocol is approved by the Antwerp University Hospital Ethics committee (UZA 11/31/224, Belgian registration number: B30020111874).

Anthropometric measurements:

All measurements are performed in the morning after an overnight fast. Height is measured to the nearest 0.5 cm using a wall-mounted stadiometer, and weight is measured using a balance beam scale with subjects in their underwear. Waist circumference is measured at the mid-level between the lower rib margin and the iliac crest. Body composition is assessed by bio-impedance analysis (BIA) and fat mass percentage is calculated using the formula of Deurenberg. Visceral abdominal adipose tissue (VAT) and subcutaneous abdominal adipose tissue (SAT) are determined by a 64-slice computerized tomography (CT) scan at the L4-L5 level (slice thickness 0.6mm).

Blood pressure is taken with a standardized method (Dynamap) after a 10-min rest, and a mean of four measurements is used. Hypertension is defined as blood pressure ≥130/85 mmHg or antihypertensive medication intake by the patient.

Presence of the metabolic syndrome is evaluated using the International Diabetes Federation criteria. Subjects are classified as having the metabolic syndrome if ≥3 of the following criteria are met: (1) increased waist circumference (men ≥94 cm, women ≥80 cm), (2) hypertriglyceridemia (≥150 mg/dl=1.7 mmol/l), (3) low HDL cholesterol (<40 mg/dl=1.03 mmol/l in men and <50 mg/dl=1.29 mmol/l in women), (4) high blood pressure (≥130/85 mmHg), (5) high fasting glucose (≥100 mg/dl).

Insulin resistance is determined using the inverse of the estimated glucose disposal rate (eGDR), calculated using the formula: : eGDR= 21.158 + (- 0.09 * waist circumference) + (- 3.407 * hypertension) + (- 0.551 * HbA1c).

Laboratory measurements:

HbA1C is determined by high performance liquid chromatography on an Adams™ A1c HA-8160 8180 , Arkray - Menarini instrument (Zaventem, Belgium; reference range: 4.8-6.0%). A mean of four annual determinations of A1C is used to assess overall metabolic control over the past two years. Plasma Serum levels of creatinin, total cholesterol, HDL cholesterol and triglycerides are measured on a Vitros 750 XRC (Ortho Clinical Diagnostic, Johnson \& Johnson, Buckinghamshire, UK) Dimension Vista 1500 System (Siemens Healthcare Diagnostics, Huizingen, Belgium) with reagents from the same manufacturer (REF K1270A for creatinin, REF K1027 for total cholesterol, REF K3048A for HDL-cholesterol, REF K2069 for triglycerides). HDL-C is measured on a Hitachi 912 (Roche Diagnostics, Mannheim, Germany). Serum creatinine is measured by an enzymatic method on a Vitros 750 (Ortho Clinical Diagnostic, Beerse, Belgium). The glomerular filtration rate (eGFR) is estimated using the abbreviated MDRD formula, including a correction factor of 0.742 for women. Plasma HMW adiponectin concentrations are measured by an enzyme-linked immunosorbent assay (ELISA) (EZHMWA-64K, Millipore, analytical sensitivity 0.5 ng/ml, intra-assay coefficient of variation [CV] 7.47%). Leptin is measured using an ELISA kit (HU Leptin kit, KAC2281, Life Technologies, sensitivity 3.5 pg/ml, intra-assay CV 5.75%). TNF-α is assayed using ELISA (HU TNF alpha kit, KHC3011, Life Technologies, sensitivity 1.7 pg/ml, intra-assay CV 6.38%) and IL-6 concentrations are measured using ELISA (HU IL-6 Chemiluminescence Elisa kit, KHC0069, Life Technologies, sensitivity 0.25 pg/ml, intra-assay CV 5.37%).

Assessment of complications:

Each subject is assessed for presence and severity of complications. 24h-Urinary albumin is measured by nephelometry Dimension Vista 1500 System (Siemens Healthcare Diagnostics, Huizingen, Belgium) with reagents from the same manufacturer (REF K7062). using a Behring Nephelometer II (Siemens Healthcare Diagnostics Products, Marburg, Germany). Microalbuminuria is defined as a urinary albumin excretion exceeding 20 µg/min. Both carotid arteries are examined using a carotid duplex scanner (General Electrics, Vivid 7 Pro), equipped with an 8-Mhz high-resolution probe.

A 64-slice non-contrast multidetector CT scan of the coronary arteries is performed to measure coronary artery calcifications (CAC) (Lightspeed, VCT; General Electric Medical Systems, Waukesha, Wis, Milwaukee, USA). Scoring is done by one skilled radiologist (R. Salgado), who is blinded to the subjects case files. Typical imaging parameters are: tube voltage 100 kv; current intensity 310 mA; rotation time 500 ms; and detector collimation 64 x 0.625 mm. Scan data are reconstructed at 75% of the cardiac cycle after the QRS complex. The radiation dose for calcium scoring range at 1.3-1.7 mSv. CAC is quantified (Agatston score) by means of a dedicated software application (SmartScore, AW). The Agatston score is the product of CAC area times the density. A score <10 is considered as normal. A score >200 is a strong predictor of CVD risk.

Standard 2-dimensional and Doppler Echocardiography (iE-33 Philips, The Netherlands) is performed by a single cardiologist blinded to the clinical status of the study participants. Briefly, left ventricular function is assessed by the parasternal long axis M-mode and modified biplane Simpson method. Diastolic function is determined taking into account all the following parameters: mitral inflow, pulmonary vein inflow signal and mitral annular tissue Doppler (tD) velocities from end expiratory cycles according to the ASE recommendations.

Being tested
observational
Keywords
type 1 diabetes, coronary artery calcifications, diastolic dysfunction, adipokines, visceral adipose tissue
Medical subject headings
Diabetes Mellitus, Type 1

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • observationalOther

    Also called no interventions; observational study

    no interventions; observational study

Study groups in NCT02689570
Study groupRoleWhat they receive
type 1 diabetic patientsAdult T1DM patients, aged 18-75 years, regularly attending the out-patient diabetes clinic of the Antwerp University Hospital are recruited starting from June 2011. Patients had to have a diabetes duration of ≥5 years and be in general good health to be included. Exclusion criteria were a history of a major adverse cardiovascular event (myocardial infarction, stroke), other cardiovascular complaints, pregnancy or a glomerular filtration rate ≤30 ml/min/1.73 m2.
Receives: Other: observational

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. coronary artery calcifications

    A 64-slice non-contrast multidetector CT scan of the coronary arteries was performed to measure coronary artery calcifications (CAC) (Lightspeed, VCT; General Electric Medical Systems, Waukesha, Wis, Milwaukee, USA). Scoring was done by one skilled radiologist (R. Salgado), who was blinded to the subjects case files. Typical imaging parameters were: tube voltage 100 kv; current intensity 310 mA; rotation time 500 ms; and detector collimation 64 x 0.625 mm. Scan data were reconstructed at 75% of the cardiac cycle after the QRS complex. The radiation dose for calcium scoring ranged at 1.3-1.7 mSv. CAC was quantified (Agatston score) by means of a dedicated software application (SmartScore, AW). The Agatston score is the product of CAC area times the density.

    Measured: once at the moment of inclusion of this cross-sectional, observational study

Secondary outcomes (1)
  1. diastolic dysfunction

    Standard 2-dimensional and Doppler Echocardiography (iE-33 Philips, The Netherlands) was performed by a single cardiologist blinded to the clinical status of the study participants. Briefly, left ventricular function was assessed by the parasternal long axis M-mode and modified biplane Simpson method. Diastolic function was determined taking into account all the following parameters: mitral inflow, pulmonary vein inflow signal and mitral annular tissue Doppler (tD) velocities from end expiratory cycles

    Measured: once at the moment of inclusion of this cross-sectional, observational study

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Feb 2016 (estimated)
  2. Study startJun 2011
  3. Primary completionJan 2017 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02689570
Sponsor's protocol ID
VISCERA
Acronym
VISCERA
Status last verified
Feb 2016
First submitted
11 Feb 2016
Last updated
24 Feb 2016
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Publications

  • De Block CEM, Shivalkar B, Goovaerts W, Brits T, Carpentier K, Verrijken A, Van Hoof V, Parizel PM, Vrints C, Van Gaal LF. Coronary artery calcifications and diastolic dysfunction versus visceral fat area in type 1 diabetes: VISCERA study. J Diabetes Complications. 2018 Mar;32(3):271-278. doi: 10.1016/j.jdiacomp.2017.11.008. Epub 2017 Nov 28.

    PubMed 29310998

Questions about this trial

What is this clinical trial studying?

An observational study of Type 1 Diabetes and Coronary Artery Calcifications, run by University Hospital, Antwerp at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 24 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Christophe EM De Block, MD, PhD (+3238214364, christophe.deblock@uza.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

coronary artery calcifications (time frame: once at the moment of inclusion of this cross-sectional, observational study). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02689570, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Feb 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in